Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    15993857 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Augmentation in Tx-resistant OCD: an Open Label Trial
Condition: Obsessive Compulsive Disorder
2 Terminated
Has Results
N-Acetylcysteine Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder
Condition: Obsessive-Compulsive Disorder
Interventions: Drug: N-Acetylcysteine;   Drug: placebo
3 Terminated
Has Results
N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD
Conditions: Borderline Personality Disorder;   Self-Injurious Behavior
Interventions: Drug: N-Acetylcysteine;   Drug: placebo
4 Completed
Has Results
Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
Conditions: Obsessive-compulsive Disorder;   Ocd
Interventions: Drug: riluzole;   Drug: placebo
5 Completed
Has Results
Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders
Conditions: Obsessive-Compulsive Disorder;   Autism Spectrum Disorder;   Autism;   Asperger Disorder;   Developmental Disorder
Interventions: Drug: Riluzole;   Drug: Placebo

Indicates status has not been verified in more than two years